| Patent application number | Description | Published |
|---|
| 20100063316 | REACTIVE PHOSPHONATES - Novel reactive phosphonate compounds are disclosed corresponding to the structural formula set forth. The reactive moiety is preferably selected from the group of Cl, I, Br, HSO | 03-11-2010 |
| 20100145066 | PHOSPHONATE COMPOUNDS - Novel phosphonate compounds are disclosed embodying an aminophosphonate moiety and a selected reaction partner. These compounds offer beneficial alternatives, and additional possibilities, to extant phosphonates and are capable of delivering desirable benefits from an application standpoint and from a compatibility standpoint broadly. | 06-10-2010 |
| 20100174110 | PROCESS FOR THE MANUFACTURE OF ALKYLAMINO ALKYLENE PHOSPHONIC ACIDS - A process for the manufacture of alkylamino alkylene phosphonic acids is disclosed. In detail, a specific phosphonate is reacted with an agent selected to yield an alkylamino moiety substituted by a radical selected from OH, OR′, NH2, NHR′, N(R′) | 07-08-2010 |
| 20100186961 | ALPHA AMINO ACID PHOSPHONIC ACID COMPOUNDS, METHOD OF PREPARATION OF USE THEREOF - Novel aminoacid alkylphosphonic acid compounds are disclosed. These compounds can be used in multiple applications, in particular in a scale inhibitor functionality in aqueous systems, including in marine oil recovery. | 07-29-2010 |
| 20110085959 | METHOD FOR THE MANUFACTURE OF CONCENTRATED PHOSPHORUS ACID - A method for the manufacture of concentrated phosphorous acid starting from pure P | 04-14-2011 |
| 20110086791 | SURFACE TREATMENT COMPOSITION CONTAINING PHOSPHONIC ACID COMPOUNDS - Surface treatment compositions containing selected phosphonic acid compounds are disclosed. The compositions contain major levels of surface-active agents in combination with additive levels of the phosphonic acid compounds, and, in accordance with needs and objectives, conventional optional ingredients and additive agents. The inventive compositions can provide significant performance benefits, among others novel synergies and eminently desirable regulatory and environmental acceptability. | 04-14-2011 |
| 20110118502 | METHOD FOR THE MANUFACTURE OF AMINOALKYLENE PHOSPHONIC ACID - A method for the manufacture of amino alkylene phosphonic acids is disclosed. Pure P | 05-19-2011 |
| 20110124533 | METHOD OF SCALE INHIBITION - A method is disclosed to inhibit scale formation in aqueous systems whereby a threshold amount of a scale inhibiting agent, represented by an aminoacid alkylphosphonic acid, is added to the aqueous system. The aminoacid moiety can be represented by α-species or by species having, at least, two or more carbon atoms between the carboxylic moiety and the amine group. These aminoacid based inhibitors exhibit unusually superior performance and system acceptability compared to leading state-of-the-art inhibitors. | 05-26-2011 |
| 20110130312 | METHOD OF SECONDARY OIL RECOVERY - A method of secondary oil recovery is disclosed wherein from 0.1 to 100 000 ppm of a medium soluble aminoalkylene phosphonic acid amine salt are used wherein both the aminoalkylene phosphonic acid moiety and the amine moiety are selected from a specifically defined class of compounds. The substantially medium soluble aminoalkylene amine phosphonates exhibit a significantly improved compatibility with the recovery medium and thus can propagate fairly freely into the medium and consequently cover a largely extended rock surface before being subject to precipitation in the form of a medium insoluble scale inhibitor. The amine compound is represented by combinations of structurally different compounds. | 06-02-2011 |
| 20110133116 | METHOD OF WATER TREATMENT - A method for securing the use of an aqueous medium under any substantial exclusion of metal ion interference is disclosed. A phosphonic acid compound containing: a selected phosphonate moiety and a moiety selected from a limited number of species; or hydrocarbon chains containing aminoalkylene phosphonic acid substituents; or alkylamino alkylene phosphonic acids containing an active moiety embodying N, O, and S. The technology can, by way of illustration, be used in numerous applications including secondary oil recovery, scale inhibition, industrial water treatment, paper pulp bleaching, dispersant treatment, sequestering application, brightness reversion avoidance and paper pulp treatment. | 06-09-2011 |
| 20120190877 | METHOD FOR THE MANUFACTURE OF DIALKYLPHOSPHITES - A method for the manufacture of dialkyl phosphites is disclosed wherein a P—O component containing from 1 to 6 P—O—P bonds in the molecule is reacted with an alcohol and a carboxylic acid ester having from 1 to 6 carbon atoms in the alkyl group and from 5 to 20 carbon atoms in the esterifying alkyl group of the ester. The dialkyl phosphites are formed under simultaneous removal by distillation of the carboxylic acid formed. | 07-26-2012 |
| Patent application number | Description | Published |
|---|
| 20090214560 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 08-27-2009 |
| 20090317402 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 12-24-2009 |
| 20100003261 | AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention andior treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 01-07-2010 |
| 20100330078 | ALPHA 5 - BETA 1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 12-30-2010 |
| 20110206681 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 08-25-2011 |
| 20120009622 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 01-12-2012 |
| 20120045443 | Agonist anti-trk-c monoclonal antibodies - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 02-23-2012 |
| 20120202285 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 08-09-2012 |
| 20120225086 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 09-06-2012 |
